*Some Market data delayed by 15 mins.

Rigel Pharmaceuticals Inc. (New)

Symbol: RIGL (NASDAQ)
0.94 ▼ (-1.26%) -0.012

Company Description:
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Key Stats
  • Today's Open: $0.9502
  • Today's High: $0.967
  • Today's Low: $0.914
  • Today's Volume: 1.04M
  • Yesterday Close: $0.953
  • Yesterday High: $0.99
  • Yesterday Low: $0.9449
  • Yesterday Volume: 390.82K
  • Last Min Volume: 100
  • Last Min High: $0.941
  • Last Min Low: $0.941
  • Last Min VWAP: $0.941
Company Profile
  • Name: Rigel Pharmaceuticals Inc. (New)
  • Website: https://www.rigel.com
  • Listed Date: 2000-11-29
  • Location: SOUTH SAN FRANCISCO, CA
  • Market Status: Active
  • CIK Number: 0001034842
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $162.50M
  • Round Lot: 100
  • Outstanding Shares: 175.41M
  • Asset Type: CS
RECENT FILINGS FOR RIGL
Filing DateFiling TypeFormat
2024-05-294View
2024-05-294View
2024-05-294View
2024-05-294View
2024-05-294View
2024-05-294View
2024-05-298-KView
2024-05-078-KView
2024-05-0710-QView
2024-04-128-KView
2024-04-10ARSView
2024-04-10DEFA14AView
2024-04-10DEF 14AView
2024-03-29PRE 14AView
2024-03-294View
2024-03-293View
2024-03-058-KView
2024-03-0510-KView
2024-03-014View
2024-03-014View
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.